Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Mevo Health vs Next Vial

Mevo Health
Graded #326

Higher grade

vs+0.9000000000000057
Next Vial
Graded #345

Lower grade

The verdict

Mevo Health takes it — 60.2/100 to 59.3/100, but only just.

Mevo Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mevo Health (Mevo Health LLC, Delaware) is a direct-pay telehealth platform offering compounded semaglutide and tirzepatide in both injection and oral-tablet forms — a rare both-routes, both-molecules menu. Next Vial is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMevo Health +16
56
40
Dose & formulationMevo Health +31
83
52
Clinical oversightNext Vial +15
67
82
Labs & monitoringEven
52
52
FulfillmentNext Vial +29
57
86
Contract termsNext Vial +35
20
55
Mevo Health · left barNext Vial · right bar

The numbers

MetricMevo HealthNext Vial
WeighScore60.2/10059.3/100
GradeCC
Scorecard rank#326#345
Semaglutide$199/mo (all doses, compounded)$250/mo (compounded)
Tirzepatide$259/mo (all doses, compounded)Not disclosed
CoverageCoverage not published49 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Mevo Health

Graded #326 · C

Strengths

  • LegitScript verification badge on multiple pages
  • Publishes the FDA compounded-medication disclaimer
  • Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
  • Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
  • Public entry-level pricing surfaced

Where it loses points

  • States served not listed on any public page
  • Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
  • No formal Medical Director role disclosed
  • Only 'as low as' entry pricing shown — no per-dose itemization
  • No SOC 2 certification claimed
Next Vial

Graded #345 · C

Strengths

  • LegitScript verified with named pharmacy partner (Manifest Pharmacy, Greer, SC)
  • No membership fees — one all-in price covering consultation, medication, and shipping
  • Compounded semaglutide, tirzepatide, and microdose options available
  • Free rushed shipping; serves 49 states nationwide
  • Board-certified physician oversight with ongoing provider support

Where it loses points

  • Tirzepatide pricing not listed publicly (starting price covers GLP-1 generally)
  • Compounded medications are not FDA-approved
  • Labs and nutritional coaching not disclosed
  • Microdose pricing not published on product page
  • Alaska not listed among served states

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard